Cardio-Oncology
Cardiac MRI accurate for suspected cardiac tumor, predictive of long-term outcomes
Cardiac MRI demonstrated high diagnostic accuracy in patients with suspected cardiac tumor and may serve as a good independent predictor of long-term survival, researchers reported.
Hodgkin lymphoma: Improving short-, long-term risks of treatment
CV safety of prostate cancer therapies ‘remains unresolved’: PRONOUNCE
In the PRONOUNCE trial, which aimed to compare the CV safety of androgen deprivation therapies for prostate cancer, there was no difference in major adverse CV events at 1 year among adults with prostate cancer and atherosclerotic CVD.
HF from cardiotoxic breast cancer therapies may confer better prognosis vs. other causes
Women who developed HF following cardiotoxic breast cancer treatment had fewer comorbidities and better overall 5-year prognosis compared with women who developed HF for other reasons, researchers reported.
Q&A: A call to action to end disparities in cardio-oncology research and care
Drivers of racial and ethnic disparities in cardio-oncology include increased risk factors among historically underrepresented groups, underrepresentation in clinical trials and socioeconomic barriers, researchers reported.
AHA donates $11 million toward cardio-oncology research on disparities
The American Heart Association announced it donated more than $11 million in research grants to four multidisciplinary teams researching disparities in cardio-oncology.
Negative impact of medical expenses high among patients with ASCVD, cancer
Difficulty paying medical bills, financial stress, cost-related nonadherence and other financial toxicities were highly prevalent among patients with atherosclerotic CVD compared with those with cancer, researchers reported.
Cardioprotective therapies fail to prevent LVEF decline in early breast cancer treatment
Neurohormonal blockade using candesartan and/or metoprolol for women undergoing treatment for early breast cancer was not significantly protective against minor long-term decline in left ventricular ejection fraction, a speaker reported.
Certain prostate cancer treatments may increase risk for HF, MI, arrhythmias
Abiraterone and gonadotropin-releasing hormone agonists for the treatment of prostate cancer may increase the likelihood of drug-related adverse cardiac events, according to data published in EClinicalMedicine.
Short-term outcomes for stroke reperfusion similar in patients with, without cancer
Among patients with cancer who experienced a stroke, reperfusion therapy conferred similar short-term outcomes as in patients with stroke and nonactive cancer or no history of cancer, researchers reported.